Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at the Rodman & Renshaw 11th Annual Healthcare Conference on September 10, 2009, at 3:15 p.m. Eastern Time at the New York Palace Hotel, New York, NY.
Rexahn`s President and Chief Operating Officer, Rick Soni, and Chief Financial Officer, Ted Jeong, will provide a strategic business overview and updates on Rexahn`s recent clinical and financing milestones, opportunities for licensing and alliances and R&D pipeline.
Rexahn currently has three drug candidates in Phase II clinical trials -Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics, and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders.
If you plan on attending the conference, and would like to arrange a one-on-one meeting with management, please contact Jennifer Song at 240-268-5300 x317 or songj@rexahn.com.
No comments:
Post a Comment